Leading companies in India’s pharma sector are increasingly focusing on specialty portfolios, diversifying into higher-value drugs, and emphasising quality and innovation. These trends are highlighted by IPA Secretary General Sudarshan Jain in his review of the sector for 2024.
Discover more from World Byte News
Subscribe to get the latest posts sent to your email.
